



#InvestEUresearch

Horizon 2020 Work Programme for Research & Innovation 2018-2020

International cooperation in health research

Rosanna D'Amario, Senior Policy Officer
Health Directorate
DG Research and Innovation
European Commission

Research and
Innovation

EU-supported health research goes global

Article 185, Joint Programming Initiatives, specific organisations

Several countries agree to set up a specific international mechanism to implement research in a specific area



HUMAN FRONTIER SCIENCE PROGRAM
FUNDING FRONTIER RESEARCH INTO COMPLEX BIOLOGICAL SYSTEMS
Supported by



Opening of research programmes – Co-funding mechanisms – Targeting of specific countries

To support the networking possibilities of researchers


Multilateral initiatives

To address global health challenges in a strategic way, with quantitative objectives and ensuring *alignment – flexibility – commitment*



Why International Collaboration?


Success rates of proposals with different numbers of applicants from non-associated countries



Note: Data for collaborative projects of Horizon 2020. Success rate is the ratio of mainlisted over eligible proposals.
Source: DG RTD - International Cooperation
Data: CORDA (JRC, EIT & art.185 not included), extraction date: 17/10/2017


Success rate in calls 2014-2016 (2017)

Success rates of proposals and numbers of mainlisted proposals with applicants from non-associated third countries



Note: Data for evaluated eligible proposals. Success rate of non-asso'd TC is 14.4%, compared to 12.2% overall H2020.
 Source: DG RTD - International Cooperation
 Data: CORDA (JRC, EIT and art.185 not included); extraction date: 28/8/2017

Flagships for international collaboration in H2020



Awareness campaign to increase international cooperation

- Global awareness raising campaign (Internet, social networks, conferences, etc.)
- National Contact Points
- Additional events in third countries (H2020 Info events)
- Roadmap and Country fiche on DG RTD / international website



International Cooperation

main features of WP 2018-2020 (1)

General opening: all topics open to international cooperation!

- ✓ **All SC1 topics are open to international cooperation**
- ✓ EC contribution: 28 MS, 16 AC and 124 Third countries (General Annexes A.) + USA
- ✓ For some other TC, co-funding mechanism (CFM): Australia, Brazil, Canada, China, Hong Kong & Macau, India, Japan, Republic of Korea, Mexico, Russia, Taiwan

International Cooperation

main features of WP 2018-2020 (2)

Topics targeting specific countries /regions (e.g. CELAC, Russian Federation, Canada, etc.)

- In calls 2014-2016: 4,3% (9.6%) participation and 2,3% (7.9%) EU contribution to TC (*)
- Need to get higher and more visible participation of TC in the last (current) WP
- Stimulate cooperation on targeted areas that represent a burden for EU and TC (e.g. cancer for CELAC)
- Give a politically visible 'sign' of cooperation (science diplomacy)

(*) Values in parentheses include also IMI2 and EDCT2 projects

Canada: SC1-BHC-05-2018

(Personalised medicine)

- International flagship collaboration with Canada for human data storage, integration and sharing to enable personalised medicine approaches
- Topic elaborated with constant exchange with the Canadian Institutes of Health Research
- At least one Canadian participant (to be co-funded by the Canadian Institutes of Health Research)
- RIA of € 4-6 million (€ 40 million)

CELAC and China: SC1-HCO-01-2018-2019-2020 (Personalised medicine)

- Topic aimed at building links with third countries; collaboration in personalised medicine
- Cooperation with CELAC (*) in 2018 and with China in 2019 (EU funding or country co-funding according to general rules)
- CSA of € 1,5-2 million

(*) At least one CELAC, but ideally several CELAC countries

Disease endemic countries: SC1-BHC-15-2018 (Infectious diseases and improving global health)

- New anti-infective agents for prevention and/or treatment of neglected infectious diseases (NID)
- The nature of the topic implies the participation of disease endemic countries
- At least one disease endemic country participant
- EU funding or country co-funding according to general rules
- RIA of € 5-10 million (€ 52 million)

CELAC: SC1-BHC-18-2018

(Infectious diseases and improving global health)

- Translational collaborative cancer research between Europe and the Community of Latin American and Caribbean States (CELAC)
- Dialogue with CELAC representatives
- EU-LAC Health (FP7 CSA) used as one of the inputs
- At least 2 different CELAC country participants
- EU funding or country co-funding according to general rules
- RIA of € 2-4 million (€ 25 million)

Russian Federation: SC1-BHC-21-2018

(Infectious diseases and improving global health)

- Research on HIV, tuberculosis (TB) and/or hepatitis C (HCV) in patients with mono-, co-infections and/or comorbidities in the context of fostering collaboration with the Russian Federation
- Co-developed with the Ministry of Education and Science of the Russian Federation
- At least one participant from Russian Federation (to be co-funded by Russia)
- RIA of € 2-3 million (€ 10 million)

International participation, in particular US, Canada, Japan, South Korea, China: SC1-HCC-03-2018 (Digital transformation in Health and Care)

- Support to further development of international cooperation in digital transformation of health and care
- At least one Third country participant, in particular US, Canada, Japan, South Korea, China
- EU-funding or country co-funding according to general rules
- CSA of up to € 2 million (€ 2 million)

Topics with particular interest for third countries participation

- ❖ SC1-BHC-16-2018: Global Alliance for Chronic Diseases (GACD) – Scaling-up of evidence-based health interventions at population level for the prevention and management of hypertension and/or diabetes (€ 20 million)
- ❖ SC1-HCO-11-2018: Strategic collaboration in health research and innovation between EU and China (€ 1 million)
- ❖ SC1-HCO-06-2018: Establishment of an International Network of Social Sciences Research Centres to help address governance and other challenges in the preparedness for and the response to infectious threats (€ 3 million)
- ❖ SC1-HCO-09-2018: Building international efforts on population and patient cohorts (€ 2 million)
- ❖ SC1-HCO-10-2018: Coordinating European brain research and developing global initiatives (€ 2 million)



More info @

- <http://ec.europa.eu/research/iscp/index.cfm> (General R&I)
- <http://ec.europa.eu/research/iscp/index.cfm?pg=participate> (Participation and co-funding)
- http://ec.europa.eu/research/participants/data/ref/h2020/other/wp/2018-2020/annexes/h2020-wp1820-annex-ga_en.pdf (Annex 1, List of countries eligible for funding)
- http://ec.europa.eu/research/participants/data/ref/h2020/grants_manual/hi/3cpart/h2020-hi-list-ac_en.pdf (List of Associated countries)
- <http://ec.europa.eu/research/iscp/index.cfm?pg=strategy> (Communication on Strategy for International cooperation)
- <http://ec.europa.eu/research/iscp/index.cfm?pg=countries> (S&T agreements)



Thank you!

@EUScienceInnov

#InvestEUresearch

#EUHealthResearch

<http://ec.europa.eu/research/health>

<http://ec.europa.eu/research/participants/portal>



European
Commission